TY - JOUR
T1 - Oncolytic viruses
T2 - perspectives on clinical development
AU - Burke, James
AU - Nieva, Jorge
AU - Borad, Mitesh J.
AU - Breitbach, Caroline J.
N1 - Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/6/15
Y1 - 2015/6/15
N2 - Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.
AB - Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.
UR - http://www.scopus.com/inward/record.url?scp=84931268628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931268628&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2015.03.020
DO - 10.1016/j.coviro.2015.03.020
M3 - Review article
C2 - 25989094
AN - SCOPUS:84931268628
SN - 1879-6257
VL - 13
SP - 55
EP - 60
JO - Current Opinion in Virology
JF - Current Opinion in Virology
M1 - 486
ER -